Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Levosalbutamol (1.25mg) + Ipratropium (500mcg)
Therapeutic Category
Asthma, Cardiovascular, General and OTC medicines, Pulmonary, Respiratory
Dosage Form
Respule
Packaging Type
Sachets
Packaging
4*5*2ml
Price
₹161.2/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Critsal 1.25 Respule is a combination of two active ingredients, Levosalbutamol (1.25mg) and Ipratropium (500mcg), designed to provide relief from respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Levosalbutamol is a selective beta-2 agonist that works by relaxing the muscles in the airways, making breathing easier. Ipratropium, an anticholinergic agent, helps to further open the airways by inhibiting the effects of acetylcholine, which constricts the bronchial muscles.
This dual-action formula makes Critsal 1.25 Respule particularly effective for individuals with bronchospasm, wheezing, and shortness of breath. By combining the bronchodilator effects of Levosalbutamol with the anticholinergic action of Ipratropium, this medication provides both immediate and sustained relief from acute symptoms of asthma and COPD, helping to improve lung function and reduce exacerbations.
Critsal 1.25 Respule is administered via a nebulizer, ensuring fast and efficient delivery of the medication directly to the lungs. It is commonly used in emergency settings or for patients who are unable to use inhalers effectively. This treatment option is beneficial for individuals who require rapid bronchodilation to ease breathing difficulties.
May cause dry mouth, cough, headache, or dizziness. Rare side effects include palpitations or nausea.
Indicated for the relief of bronchospasm in patients with asthma and COPD, and to prevent acute episodes of wheezing and shortness of breath.
Consult a healthcare provider before use, especially if you have a history of heart disease, glaucoma, or urinary retention.
Store at room temperature, away from heat and moisture. Keep the vial tightly closed and out of reach of children.
Composition : Levosalbutamol (1.25mg) + Budesonide (0.5mg) Respule
Composition : Formoterol (20mcg) + Budesonide (0.5mg) Respule
Composition : Salmeterol (50mcg) + Fluticasone Propionate (250mcg)
Composition : Fluticasone Propionate 250mcg + Formoterol Fumarate 6mcg Life Cap
Composition : Salmeterol (50mcg) + Fluticasone Propionate (500 mcg)
Composition : Formoterol (6mcg) + Budesonide (200mcg) Inhaler
Composition : Fluticasone Propionate 500mcg + Formoterol Fumarate 12mcg Life Cap
Composition : Formoterol 6mcg + Budesonide 400mcg Rota Capsule
Composition : Salmeterol (25mcg) + Fluticasone Propionate (250mcg)
Composition : Salmeterol (25mcg) + Fluticasone Propionate (500mcg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This combination respule is used in nebulization therapy for asthma, COPD, bronchospasm, and acute respiratory distress. It combines a fast-acting bronchodilator (levosalbutamol) with an anticholinergic agent (ipratropium), making it a strong hospital-care and respiratory segment product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from strong demand in hospitals, ICUs, emergency wards, and respiratory clinics. It is widely used for acute asthma and COPD exacerbations, ensuring consistent institutional orders and high-value repeat usage.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for respiratory and nebulization formulations with monopoly rights, quality manufacturing standards, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from hospital procurement, ICU demand, emergency respiratory care usage, chronic COPD management, and steady institutional business when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this nebulization combination can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, product availability, and distribution support services.